Targeted treatment of colorectal cancer, BRAF V600E gene mutation targeted therapy of colorectal cancer Braftovi + Erbitux finally achieved positive resultsColorectal cancer treatment statusColorectal cancer is one of the most c..
How to prevent relapse of colorectal cancer, how to treat relapse of colorectal cancer after surgery?Colorectal cancer is a common malignant tumor, including colon cancer and rectal cancer. The incidence of colorectal cancer fro..
Intestinal cancer self-test, how to check intestinal cancer, colorectal cancer screening, rectal cancer check, what check for rectal cancer, what check for suspected bowel cancer.Bowel cancer (usually referred to as colorectal can..
A meal "eats" colorectal cancer In 2014, 65-year-old Mr. Yang and his wife traveled abroad. During the period, gastrointestinal discomfort and constipation symptoms occurred, but they didn't pay much attention at that time, thinki..
"About 5-6 years ago, we started to see some young patients with colorectal cancer, including some people in their 20s or 30s, which had never been seen before," Memorial Sloan Kettering Cancer Center (MSK ) Said Dr. Julio Garci..
In the past two years, with the deepening of research related to targeting and immunotherapy and genotyping, more and more drugs with good effects and fewer side effects have become new options for individualized treatment and c..
Medical personnel worldwide are developing new human antigen vaccines, including various types of cancer preventive and therapeutic. Click for details: The light of hope to end cancer-2019 global inventory of the latest cancer vac..
Before the start of the article, the first look at science.Understanding of MSI-H, MSS, MSI-LMSS (MicroSatellite stability), microsatellite stability, compared with MSI, there is no obvious MSI.MSI-H (MicroSatellite Instability-..
BRAF mutations occur in 15% of colorectal patients. There are no targeted drugs approved by the FDA so far, and the prognosis is poor. Among them, BRAF V600E is the most common mutation.Recently, the results of the Phase III BEACO..
The theme of the 2019 NCCN Annual Meeting is to expand biomarker testing to guide the precise treatment of cancer, as well as new changes to colorectal cancer (CRC) guidelines. The 5-year survival rate of colorectal cancer is onl..